We compare the effect on inflammation of the commonly used lipid emulsions n-3-rich and n-6-rich in human peripheral blood mononuclear cells.
This review of randomized controlled trials and cohort studies analyses the impact of exclusive and partial enteral nutrition v. corticosteroids on intestinal microbiota, mucosal healing as well as other clinically important outcomes, including clinical remission, relapse, adherence, adverse events and health-related quality of life in pediatric Crohn's disease.
Nutrition is an important consideration in the care of children with inflammatory bowel disease to achieve optimal health, correct nutritional deficiencies, achieve weight restoration and maintenance, and complete normative linear growth.
This study characterizes the practices and perceptions of gastroenterologists regarding the use of enteral nutrition in patients with inflammatory bowel disease in one of the largest countries in the Gulf region.
This review addresses the common indications for use of parenteral nutrition, the composition of parenteral nutrition, and the possible complications encountered with parenteral nutrition use, as well as scenarios of inappropriate parenteral nutrition use among patients with inflammatory bowel diseases.
This analysis covers a wide range of topics, from the well-established diets to the new nutritional theories, along with the recent progress in emerging research fields, such as nutrigenomics.
The aim of this study was to investigate the long-term outcomes of patients with Crohn's disease after initiation of home parenteral nutrition.
This study demonstrates that preoperative exclusive enteral nutrition is achievable in pediatric Crohn Disease patients undergoing right hemicolectomy and is associated with positive peri-operative outcomes.
The aim of the study was to evaluate short- and long-term outcomes of exclusive enteral nutrition versus corticosteroids as induction therapy, in pediatric patients with Crohn's disease.
We present a case study of a patient with Crohn's disease, on dual immunosuppression with infliximab and mercaptopurine presenting with inflammatory small bowel obstruction and COVID-19 infection.